



PRESS RELEASE

Stallergenes' circular in response to the takeover bid initiated by Ares Life Sciences S.à.r.l., approved by the AMF, and other information relating to Stallergenes have been made available to the public

BID PRICE: € 59 FOR EACH STALLERGENES SHARE

TERM OF THE BID: 25 TRADING DAYS

The timetable for the bid will be set by the AMF

This press release has been prepared and published by Stallergenes ("the Company" hereafter), according to the provisions of Articles 231–27 3° and 231–28 I of the General Regulations of the AMF.

Pursuant to Article L. 621-8 of the Monetary and Finance Code and Article 231-26 of its General Regulations, on 6 January 2011, the AMF issued its approval, under number 11–006, of the circular prepared by the Company in response to the takeover bid initiated by Ares Life Sciences I S.à.r.l.

In accordance with the provisions of Article 231-28 of the General Regulations of the AMF, the legal, financial and accounting information relating to the Company was also made available to the public today.

The circular in response to the bid and the main legal, financial and accounting information relating to the Company are available (in French language only) on the AMF website (www.amf-france.org), and on the Stallergenes website (finance.stallergenes.com). These documents are also available to the public free of charge at Stallergenes' head office, located at 6, rue Alexis de Tocqueville, 92183 Antony, France.